Zydus Lifesciences Ltd.

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Verapamil Hydrochloride Extended-Release Tablets USP, 120 mg, 180 mg and 240 mg (USRLD: Calan SR Extended-Release Tablets, 120 mg, 180 mg and 240 mg). Verapamil Hydrochloride Extended-Release Tablets (120 mg, 180 mg, and 240 mg) are used to lower high blood pressure, which helps reduce the risk of serious heart problems like strokes and heart attacks.

Verapamil Hydrochloride Extended-Release Tablets will be produced at Zydus Lifesciences, Baddi, Himachal Pradesh. Verapamil Hydrochloride Extended-Release Tablets had annual sales of $24.5 million in the United States (IQVIA MAT September-2025). The group now has 428 approvals and has so far filed 487 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.